Clinical trial · Observational
Obinutuzumab in Chinese Real-world Patients With iNHL
Efficacy and Safety of Obinutuzumab in Chinese Patients With Indolent Non-Hodgkin's B-cell Lymphoma in the Real-World.
NCT05968001CI-TRIAL-00068389unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to assess the clinical efficacy and safety of obinutuzumab in Chinese patients with indolent non-Hodgkin B-cell Lymphoma (predominantly Follicular lymphoma and Marginal zone lymphoma) in a real-world setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphomas Non-Hodgkin's B-Cell | B-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Obinutuzumab | Drug | Obinutuzumab | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1
- description
- the younger cohort (aged ≥ 18 and \< 60 years at the start of treatment)
- interventionNames
- Drug: Obinutuzumab
- label
- Cohort 2
- description
- the older cohort (aged ≥ 60 years at the start of treatment)
- interventionNames
- Drug: Obinutuzumab
Primary outcomes (1)
- measure
- Efficacy Endpoints
- timeFrame
- 12 months
- description
- The best objective response rate (ORR), and CR rate; ORR and CR rate at the end of treatment; DCR, DoR, TTNT, PFS, DFS, and OS.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age: Age ≥ 18 years at the start of treatment; * Be diagnosed with grade 1-3a follicular Lymphoma, Marginal zone lymphoma; * Previously untreated or relapsed or refractory patients; * Patients who started treatment with otuzumab between June 2021 and April 2023. Exclusion Criteria: * Patients currently participating or planning to participate in any interventional clinical trial; * Patients who, in the opinion of the investigator, are Discomfort for any other reason to participate in this study.
References
Publications (0)
Data not yet available
No reference posted for this study.